Omnicell (OMCL) Expected to Announce Earnings on Tuesday

Omnicell (NASDAQ:OMCL) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.16 per share and revenue of $260.18 million for the quarter. Omnicell has set its Q1 2025 guidance at 0.150-0.250 EPS and its FY 2025 guidance at 1.650-1.850 EPS.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Omnicell Stock Performance

OMCL stock opened at $31.16 on Monday. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of 115.41, a PEG ratio of 7.53 and a beta of 0.78. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. The business’s fifty day simple moving average is $33.47 and its two-hundred day simple moving average is $40.45.

Analyst Ratings Changes

OMCL has been the subject of a number of research analyst reports. Benchmark reiterated a “buy” rating and set a $62.00 price objective on shares of Omnicell in a report on Tuesday, February 4th. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Saturday. Bank of America dropped their price objective on Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research note on Monday, January 6th. Wells Fargo & Company lowered their target price on Omnicell from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Finally, JPMorgan Chase & Co. dropped their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $50.67.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.